WASHINGTON, AUG. 19, 2013 — Approach shows promise but fails to gain traction in real-world implementation
WASHINGTON, Aug. 19, 2013 /PRNewswire-USNewswire/ -- A National Pharmaceutical Council (NPC) study published in the peer-reviewed journal Pharmacy and Therapeutics details new work in developing, testing and piloting a more structured approach to formulary decision-making.
The study, "Transparency in Evidence Evaluation and Formulary Decision-Making," discusses efforts to increase the clarity, consistency, and transparency of how evidence is applied by payers during the formulary decision-making process. During the project, the new approach was evaluated in a pharmacy and therapeutics setting.
"Right now, there is a bit of a 'black box' around the formulary decision-making process," said Robert Dubois, MD, Ph.D., NPC's chief science officer and an author of the study. "As a result, decisions about treatment access are often unpredictable to patients, providers and biopharmaceutical manufacturers. We sought to identify ways to clarify the process."
The project, conducted with Cerner Research and other research experts, and sponsored in part by Pfizer Inc, was completed in three phases. First, an expert panel was leveraged to create an evidence assessment tool based on the core elements of formulary decision-making: safety, efficacy, cost and certainty of evidence. Next, the evidence assessment tool was validated by surveying a larger group of medical and pharmacy directors. Finally, the tool was piloted in a real-world pharmacy and therapeutics (P&T) environment.
to read the full story click her http://www.heraldonline.com/2013/08/19/5127455/national-pharmaceutical-council.html
No comments:
Post a Comment